We found significant differences in CM of the 10-gene marker panel by IHC subtype of the primary BC, indicating that our marker panel may predict detailed characteristics about the initial diagnosis of HER2-positive cancer regardless of the status of hormone receptors (Supplementary Table 2 and Supplementary Fig. 4). This evidence concerns the gene ERBB2 and cancer.